Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals Inc., a for-profit biotechnology company headquartered in Durham, North Carolina, supplies specialized pharmaceutical products to the federal government as a prime contractor exclusively — no subcontract activity — under the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and a newly awarded Blanket Purchase Agreement with the VA's National Acquisition Center. The company competes in the open market without set-aside designations across all recent federal awards.

Biocryst's federal capability portfolio centers on two FDA-approved small-molecule drugs for rare and critical medical conditions: ORLADEYO (berotralstat) for hereditary angioedema and RAPIVAB (peramivir) for influenza treatment. Representative prime work includes a $69.4 million delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response on September 30, 2024, for Peramivir supply through September 29, 2025, and a newly awarded $93 million single-award BPA from the VA's National Acquisition Center (effective June 3, 2026, through June 2, 2027) covering both ORLADEYO and RAPIVAB for expedited procurement across federal healthcare programs. Biocryst has also received recurring delivery orders from the Veterans Integrated Service Network 20 for bulk ORLADEYO supplies, including a $379.9 million order awarded October 1, 2024, for berotralstat HCL 150mg capsules.

Customer concentration skews heavily toward two agencies. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response and the VA National Acquisition Center together account for 86% of combined potential value ($447.2 million out of $628.9 million total). Within that aggregate, HHS ASPR anchors six awards at $343.6 million combined potential value — predominantly the large peramivir delivery order — while the VA National Acquisition Center holds three awards at $103.6 million. By award count, the rankings shift: Veterans Integrated Service Network 20 leads with twelve awards valued at $2.4 million combined (recurring small-to-moderate ORLADEYO orders), followed by ASPR (six awards) and the VA NAC (three awards). The National Institutes of Health National Institute of Allergy and Infectious Diseases contributes two research awards at $88 million combined potential value, indicating Biocryst's participation in federal biodefense or pandemic-preparedness R&D funding.

Biocryst holds two parent vehicles: the GSA Pharmaceuticals and Drugs Federal Supply Schedule (17 task orders, $174.8 million combined potential value) and the newly established VA NAC BPA ($93 million ceiling, single award). The FSS serves as the underlying contracting mechanism for nearly all delivery orders from Veterans Integrated Service Network regional facilities and ASPR. Activity accelerated significantly in 2024 (seven awards) and continues in 2025–2026 (three awards each year), though the recompete exposure over the next twenty-four months is minimal — only three awards with combined potential value of $541 thousand reaching ultimate completion in that window. The $93 million BPA awarded in June 2026 establishes a fresh procurement vehicle running through June 2027, reducing near-term recompete pressure. Service Contract Inventory data capture one SCI-reportable record in FY2022 valued at $655 thousand with 0.2 FTEs, reflecting Biocryst's positioning primarily as a goods/pharmaceutical supplier rather than a labor-intensive services contractor; SCI does not capture Biocryst's substantial product-delivery revenue streams on the FSS or BPA.